Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olaparib - AstraZeneca

Drug Profile

Olaparib - AstraZeneca

Alternative Names: AZD 221; AZD-2281; KU-0059436; KU-59436; Lynparza; MK 7339

Latest Information Update: 12 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KuDOS Pharmaceuticals; University of Pennsylvania
  • Developer AstraZeneca; Cancer Research UK; Dana-Farber Cancer Institute; European Network of Gynaecological Oncological Trial Groups; German Breast Group; M. D. Anderson Cancer Center; Mario Negri Institute for Pharmacological Research; Massachusetts General Hospital; Merck & Co; Merck Sharp & Dohme; Myriad Genetic Laboratories; Myriad Genetics; National Cancer Institute (USA); National Institute of Oncology; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Spanish Oncology Genito-Urinary Group; University Health Network; University of Manchester; University of Oxford; University of Sydney; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Ketones; Phthalazines; Piperazines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Fallopian tube cancer; Breast cancer; Pancreatic cancer; Peritoneal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer
  • Phase III Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
  • Phase II Bladder cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Osteosarcoma; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Phase I/II Glioblastoma

Most Recent Events

  • 30 Jun 2021 AstraZeneca and University of Oxford complete Phase-II clinical trials in Fallopian tube cancer, Ovarian cancer and Peritoneal cancer (Combination therapy, In adults, In adolescents) in United Kingdom (PO) (EudraCT2016-000559-28)
  • 24 Jun 2021 Registered for Prostate cancer (Hormone refractory, Metastatic disease, Late-stage disease, Second-line therapy or greater, Monotherapy) in China (PO)
  • 23 Jun 2021 Preregistration for Prostate cancer (Hormone refractory, Metastatic disease, Late-stage disease, Second-line therapy or greater, Monotherapy) in China (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top